Literature DB >> 8352192

Anti-streptokinase antibodies inhibit fibrinolytic effects of anistreplase in acute myocardial infarction.

J Brügemann1, J van der Meer, V J Bom, W van der Schaaf, P A de Graeff, K I Lie.   

Abstract

Entities:  

Mesh：

Substances：

Year:  1993        PMID： 8352192     DOI： 10.1016/0002-9149(93)91143-6

Source DB:  PubMed          Journal:  Am J Cardiol        ISSN： 0002-9149            Impact factor:   2.778


× No keyword cloud information.
  6 in total

Review 1.  Is the development of antibodies to streptokinase clinically relevant?

Authors:  M B Buchalter
Journal:  Drugs       Date:  1994-08       Impact factor: 9.546

Review 2.  Does the potential for development of streptokinase antibodies change the risk-benefit ratio in older patients?

Authors:  J Brügemann; P A de Graeff; J van der Meer; K I Lie
Journal:  Drugs Aging       Date:  1995-08       Impact factor: 3.923

3.  Antibodies to streptokinase.

Authors:  K Jennings
Journal:  BMJ       Date:  1996-02-17

4.  Streptokinase antibodies are of clinical importance and they can be measured in half an hour by a simple enzyme-linked immunosorbent assay.

Authors:  J Brügemann; J van der Meer; V J Bom; K I Lie
Journal:  Br Heart J       Date:  1994-08

5.  Neutralising antibodies after streptokinase treatment for myocardial infarction: a persisting puzzle.

Authors:  K McGrath; C Hogan; D Hunt; C O'Malley; N Green; R Dauer; A Dalli
Journal:  Br Heart J       Date:  1995-08

Review 6.  How safe is the readministration of streptokinase?

Authors:  H S Lee
Journal:  Drug Saf       Date:  1995-08       Impact factor: 5.606
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.